These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10519908)

  • 1. Structure-activity relationships of beta-amino acid-containing integrin antagonists.
    Scarborough RM
    Curr Med Chem; 1999 Oct; 6(10):971-81. PubMed ID: 10519908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids.
    Belvisi L; Bernardi A; Colombo M; Manzoni L; Potenza D; Scolastico C; Giannini G; Marcellini M; Riccioni T; Castorina M; LoGiudice P; Pisano C
    Bioorg Med Chem; 2006 Jan; 14(1):169-80. PubMed ID: 16214345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins.
    Miller LM; Pritchard JM; Macdonald SJF; Jamieson C; Watson AJB
    J Med Chem; 2017 Apr; 60(8):3241-3251. PubMed ID: 28135089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
    Hall ER; Bibby LI; Slack RJ
    Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ligand recognition specificity of beta3 integrins.
    Suehiro K; Smith JW; Plow EF
    J Biol Chem; 1996 Apr; 271(17):10365-71. PubMed ID: 8626608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.
    Osterkamp F; Ziemer B; Koert U; Wiesner M; Raddatz P; Goodman SL
    Chemistry; 2000 Feb; 6(4):666-83. PubMed ID: 10807178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.
    Sulyok GA; Gibson C; Goodman SL; Hölzemann G; Wiesner M; Kessler H
    J Med Chem; 2001 Jun; 44(12):1938-50. PubMed ID: 11384239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrins in drug targeting-RGD templates in toxins.
    Lu X; Lu D; Scully MF; Kakkar VV
    Curr Pharm Des; 2006; 12(22):2749-69. PubMed ID: 16918409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and chemical synthesis of integrin ligands.
    Heckmann D; Kessler H
    Methods Enzymol; 2007; 426():463-503. PubMed ID: 17697896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction Mechanism and Clustering among RGD Peptides and Integrins.
    Dong X; Yu Y; Wang Q; Xi Y; Liu Y
    Mol Inform; 2017 May; 36(5-6):. PubMed ID: 28004516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
    Dresner-Pollak R; Rosenblatt M
    J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
    Sun CC; Qu XJ; Gao ZH
    Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
    Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
    Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins.
    Bazan-Socha S; Kisiel DG; Young B; Theakston RD; Calvete JJ; Sheppard D; Marcinkiewicz C
    Biochemistry; 2004 Feb; 43(6):1639-47. PubMed ID: 14769041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic RGD-containing alpha-helical coiled coil peptides promote integrin-dependent cell adhesion.
    Villard V; Kalyuzhniy O; Riccio O; Potekhin S; Melnik TN; Kajava AV; Rüegg C; Corradin G
    J Pept Sci; 2006 Mar; 12(3):206-12. PubMed ID: 16103993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naturally occurring point mutation in the beta3 integrin MIDAS-like domain affects differently alphavbeta3 and alphaIIIbbeta3 receptor function.
    Morel-Kopp MC; Melchior C; Chen P; Ammerlaan W; Lecompte T; Kaplan C; Kieffer N
    Thromb Haemost; 2001 Dec; 86(6):1425-34. PubMed ID: 11776310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin.
    Langner J; Neumann B; Goodman SL; Pawlita M
    Arch Virol; 2004 Oct; 149(10):1877-96. PubMed ID: 15290355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.
    Engleman VW; Nickols GA; Ross FP; Horton MA; Griggs DW; Settle SL; Ruminski PG; Teitelbaum SL
    J Clin Invest; 1997 May; 99(9):2284-92. PubMed ID: 9151803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
    Dechantsreiter MA; Planker E; Mathä B; Lohof E; Hölzemann G; Jonczyk A; Goodman SL; Kessler H
    J Med Chem; 1999 Aug; 42(16):3033-40. PubMed ID: 10447947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex.
    Calvete JJ
    Thromb Haemost; 1994 Jul; 72(1):1-15. PubMed ID: 7974356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.